nodes	percent_of_prediction	percent_of_DWPC	metapath
Nitrofurantoin—ABCG2—Teniposide—lymphatic system cancer	0.307	0.404	CbGbCtD
Nitrofurantoin—ABCG2—Mitoxantrone—lymphatic system cancer	0.215	0.283	CbGbCtD
Nitrofurantoin—ABCG2—Vincristine—lymphatic system cancer	0.148	0.195	CbGbCtD
Nitrofurantoin—ABCG2—Methotrexate—lymphatic system cancer	0.0896	0.118	CbGbCtD
Nitrofurantoin—Haemoglobin decreased—Mitoxantrone—lymphatic system cancer	0.00198	0.00826	CcSEcCtD
Nitrofurantoin—Nystagmus—Vincristine—lymphatic system cancer	0.00196	0.00817	CcSEcCtD
Nitrofurantoin—Interstitial lung disease—Mitoxantrone—lymphatic system cancer	0.00193	0.00803	CcSEcCtD
Nitrofurantoin—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.00185	0.0077	CcSEcCtD
Nitrofurantoin—Numbness—Vincristine—lymphatic system cancer	0.00169	0.00704	CcSEcCtD
Nitrofurantoin—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.00168	0.007	CcSEcCtD
Nitrofurantoin—Sensory loss—Vincristine—lymphatic system cancer	0.00162	0.00674	CcSEcCtD
Nitrofurantoin—Alopecia—Mechlorethamine—lymphatic system cancer	0.00157	0.00654	CcSEcCtD
Nitrofurantoin—Lung infiltration—Methotrexate—lymphatic system cancer	0.00145	0.00604	CcSEcCtD
Nitrofurantoin—Neuropathy peripheral—Teniposide—lymphatic system cancer	0.00143	0.00596	CcSEcCtD
Nitrofurantoin—Interstitial pneumonia—Methotrexate—lymphatic system cancer	0.00141	0.00586	CcSEcCtD
Nitrofurantoin—Vertigo—Mechlorethamine—lymphatic system cancer	0.00139	0.00579	CcSEcCtD
Nitrofurantoin—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00138	0.00577	CcSEcCtD
Nitrofurantoin—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00127	0.0053	CcSEcCtD
Nitrofurantoin—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00126	0.00526	CcSEcCtD
Nitrofurantoin—Renal failure—Fludarabine—lymphatic system cancer	0.00126	0.00525	CcSEcCtD
Nitrofurantoin—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.00126	0.00524	CcSEcCtD
Nitrofurantoin—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00124	0.00515	CcSEcCtD
Nitrofurantoin—Diabetes mellitus—Carmustine—lymphatic system cancer	0.00122	0.0051	CcSEcCtD
Nitrofurantoin—Anorexia—Mechlorethamine—lymphatic system cancer	0.0012	0.00501	CcSEcCtD
Nitrofurantoin—Chills—Teniposide—lymphatic system cancer	0.00118	0.0049	CcSEcCtD
Nitrofurantoin—Alopecia—Teniposide—lymphatic system cancer	0.00116	0.00482	CcSEcCtD
Nitrofurantoin—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.00115	0.00477	CcSEcCtD
Nitrofurantoin—Eruption—Methotrexate—lymphatic system cancer	0.0011	0.0046	CcSEcCtD
Nitrofurantoin—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.0011	0.00457	CcSEcCtD
Nitrofurantoin—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00109	0.00454	CcSEcCtD
Nitrofurantoin—Anaemia—Teniposide—lymphatic system cancer	0.00105	0.00439	CcSEcCtD
Nitrofurantoin—Chills—Fludarabine—lymphatic system cancer	0.00103	0.0043	CcSEcCtD
Nitrofurantoin—Leukopenia—Teniposide—lymphatic system cancer	0.00102	0.00425	CcSEcCtD
Nitrofurantoin—Alopecia—Fludarabine—lymphatic system cancer	0.00102	0.00424	CcSEcCtD
Nitrofurantoin—Liver disorder—Methotrexate—lymphatic system cancer	0.000997	0.00415	CcSEcCtD
Nitrofurantoin—Chest pain—Teniposide—lymphatic system cancer	0.000971	0.00405	CcSEcCtD
Nitrofurantoin—Interstitial lung disease—Methotrexate—lymphatic system cancer	0.00096	0.004	CcSEcCtD
Nitrofurantoin—Cyanosis—Methotrexate—lymphatic system cancer	0.00096	0.004	CcSEcCtD
Nitrofurantoin—Confusional state—Teniposide—lymphatic system cancer	0.000938	0.00391	CcSEcCtD
Nitrofurantoin—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00093	0.00388	CcSEcCtD
Nitrofurantoin—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00093	0.00387	CcSEcCtD
Nitrofurantoin—Anaemia—Fludarabine—lymphatic system cancer	0.000926	0.00386	CcSEcCtD
Nitrofurantoin—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.000916	0.00381	CcSEcCtD
Nitrofurantoin—Thrombocytopenia—Teniposide—lymphatic system cancer	0.000911	0.0038	CcSEcCtD
Nitrofurantoin—Malaise—Fludarabine—lymphatic system cancer	0.000904	0.00377	CcSEcCtD
Nitrofurantoin—Leukopenia—Fludarabine—lymphatic system cancer	0.000897	0.00374	CcSEcCtD
Nitrofurantoin—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.000892	0.00372	CcSEcCtD
Nitrofurantoin—Pleural effusion—Methotrexate—lymphatic system cancer	0.000888	0.0037	CcSEcCtD
Nitrofurantoin—Anorexia—Teniposide—lymphatic system cancer	0.000887	0.0037	CcSEcCtD
Nitrofurantoin—Cough—Fludarabine—lymphatic system cancer	0.000875	0.00364	CcSEcCtD
Nitrofurantoin—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.000873	0.00364	CcSEcCtD
Nitrofurantoin—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000864	0.0036	CcSEcCtD
Nitrofurantoin—Myalgia—Fludarabine—lymphatic system cancer	0.000853	0.00356	CcSEcCtD
Nitrofurantoin—Discomfort—Fludarabine—lymphatic system cancer	0.000843	0.00351	CcSEcCtD
Nitrofurantoin—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00084	0.0035	CcSEcCtD
Nitrofurantoin—Dyspnoea—Teniposide—lymphatic system cancer	0.00083	0.00346	CcSEcCtD
Nitrofurantoin—Confusional state—Fludarabine—lymphatic system cancer	0.000825	0.00344	CcSEcCtD
Nitrofurantoin—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.000818	0.00341	CcSEcCtD
Nitrofurantoin—Decreased appetite—Teniposide—lymphatic system cancer	0.000809	0.00337	CcSEcCtD
Nitrofurantoin—Renal failure—Carmustine—lymphatic system cancer	0.000807	0.00336	CcSEcCtD
Nitrofurantoin—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.000805	0.00335	CcSEcCtD
Nitrofurantoin—Vomiting—Mechlorethamine—lymphatic system cancer	0.000803	0.00334	CcSEcCtD
Nitrofurantoin—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.000801	0.00334	CcSEcCtD
Nitrofurantoin—Rash—Mechlorethamine—lymphatic system cancer	0.000796	0.00332	CcSEcCtD
Nitrofurantoin—Anorexia—Fludarabine—lymphatic system cancer	0.00078	0.00325	CcSEcCtD
Nitrofurantoin—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.000768	0.0032	CcSEcCtD
Nitrofurantoin—Feeling abnormal—Teniposide—lymphatic system cancer	0.000767	0.0032	CcSEcCtD
Nitrofurantoin—Drowsiness—Mitoxantrone—lymphatic system cancer	0.000763	0.00318	CcSEcCtD
Nitrofurantoin—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000761	0.00317	CcSEcCtD
Nitrofurantoin—Chills—Bleomycin—lymphatic system cancer	0.000757	0.00316	CcSEcCtD
Nitrofurantoin—Renal failure—Mitoxantrone—lymphatic system cancer	0.00075	0.00313	CcSEcCtD
Nitrofurantoin—Nausea—Mechlorethamine—lymphatic system cancer	0.00075	0.00312	CcSEcCtD
Nitrofurantoin—Alopecia—Bleomycin—lymphatic system cancer	0.000746	0.00311	CcSEcCtD
Nitrofurantoin—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000745	0.00311	CcSEcCtD
Nitrofurantoin—Abdominal pain—Teniposide—lymphatic system cancer	0.000736	0.00307	CcSEcCtD
Nitrofurantoin—Body temperature increased—Teniposide—lymphatic system cancer	0.000736	0.00307	CcSEcCtD
Nitrofurantoin—Paraesthesia—Fludarabine—lymphatic system cancer	0.000735	0.00306	CcSEcCtD
Nitrofurantoin—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000733	0.00305	CcSEcCtD
Nitrofurantoin—Dyspnoea—Fludarabine—lymphatic system cancer	0.000729	0.00304	CcSEcCtD
Nitrofurantoin—Dyspepsia—Fludarabine—lymphatic system cancer	0.00072	0.003	CcSEcCtD
Nitrofurantoin—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.000712	0.00297	CcSEcCtD
Nitrofurantoin—Decreased appetite—Fludarabine—lymphatic system cancer	0.000711	0.00296	CcSEcCtD
Nitrofurantoin—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000706	0.00294	CcSEcCtD
Nitrofurantoin—Hypoaesthesia—Vincristine—lymphatic system cancer	0.0007	0.00292	CcSEcCtD
Nitrofurantoin—Constipation—Fludarabine—lymphatic system cancer	0.000699	0.00291	CcSEcCtD
Nitrofurantoin—Vasculitis—Methotrexate—lymphatic system cancer	0.000696	0.0029	CcSEcCtD
Nitrofurantoin—Hypersensitivity—Teniposide—lymphatic system cancer	0.000686	0.00286	CcSEcCtD
Nitrofurantoin—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000685	0.00285	CcSEcCtD
Nitrofurantoin—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000682	0.00284	CcSEcCtD
Nitrofurantoin—Anaemia—Bleomycin—lymphatic system cancer	0.000679	0.00283	CcSEcCtD
Nitrofurantoin—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000674	0.00281	CcSEcCtD
Nitrofurantoin—Asthenia—Teniposide—lymphatic system cancer	0.000668	0.00278	CcSEcCtD
Nitrofurantoin—Malaise—Bleomycin—lymphatic system cancer	0.000663	0.00276	CcSEcCtD
Nitrofurantoin—Leukopenia—Bleomycin—lymphatic system cancer	0.000658	0.00274	CcSEcCtD
Nitrofurantoin—Alopecia—Carmustine—lymphatic system cancer	0.000651	0.00271	CcSEcCtD
Nitrofurantoin—Body temperature increased—Fludarabine—lymphatic system cancer	0.000647	0.00269	CcSEcCtD
Nitrofurantoin—Cough—Bleomycin—lymphatic system cancer	0.000641	0.00267	CcSEcCtD
Nitrofurantoin—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.000638	0.00266	CcSEcCtD
Nitrofurantoin—Diarrhoea—Teniposide—lymphatic system cancer	0.000637	0.00265	CcSEcCtD
Nitrofurantoin—Chest pain—Bleomycin—lymphatic system cancer	0.000626	0.00261	CcSEcCtD
Nitrofurantoin—Myalgia—Bleomycin—lymphatic system cancer	0.000626	0.00261	CcSEcCtD
Nitrofurantoin—Alopecia—Vincristine—lymphatic system cancer	0.000622	0.00259	CcSEcCtD
Nitrofurantoin—Discomfort—Bleomycin—lymphatic system cancer	0.000618	0.00258	CcSEcCtD
Nitrofurantoin—Chills—Mitoxantrone—lymphatic system cancer	0.000615	0.00256	CcSEcCtD
Nitrofurantoin—Alopecia—Mitoxantrone—lymphatic system cancer	0.000605	0.00252	CcSEcCtD
Nitrofurantoin—Confusional state—Bleomycin—lymphatic system cancer	0.000605	0.00252	CcSEcCtD
Nitrofurantoin—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000603	0.00251	CcSEcCtD
Nitrofurantoin—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.0006	0.0025	CcSEcCtD
Nitrofurantoin—Anaemia—Carmustine—lymphatic system cancer	0.000593	0.00247	CcSEcCtD
Nitrofurantoin—Vomiting—Teniposide—lymphatic system cancer	0.000592	0.00247	CcSEcCtD
Nitrofurantoin—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000587	0.00245	CcSEcCtD
Nitrofurantoin—Asthenia—Fludarabine—lymphatic system cancer	0.000587	0.00245	CcSEcCtD
Nitrofurantoin—Rash—Teniposide—lymphatic system cancer	0.000587	0.00245	CcSEcCtD
Nitrofurantoin—Headache—Teniposide—lymphatic system cancer	0.000583	0.00243	CcSEcCtD
Nitrofurantoin—Leukopenia—Carmustine—lymphatic system cancer	0.000574	0.00239	CcSEcCtD
Nitrofurantoin—Anorexia—Bleomycin—lymphatic system cancer	0.000572	0.00238	CcSEcCtD
Nitrofurantoin—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000567	0.00236	CcSEcCtD
Nitrofurantoin—Anaemia—Vincristine—lymphatic system cancer	0.000566	0.00236	CcSEcCtD
Nitrofurantoin—Diarrhoea—Fludarabine—lymphatic system cancer	0.00056	0.00233	CcSEcCtD
Nitrofurantoin—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000553	0.00231	CcSEcCtD
Nitrofurantoin—Nausea—Teniposide—lymphatic system cancer	0.000553	0.0023	CcSEcCtD
Nitrofurantoin—Anaemia—Mitoxantrone—lymphatic system cancer	0.000551	0.0023	CcSEcCtD
Nitrofurantoin—Vertigo—Vincristine—lymphatic system cancer	0.00055	0.00229	CcSEcCtD
Nitrofurantoin—Leukopenia—Vincristine—lymphatic system cancer	0.000548	0.00228	CcSEcCtD
Nitrofurantoin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000546	0.00228	CcSEcCtD
Nitrofurantoin—Chest pain—Carmustine—lymphatic system cancer	0.000546	0.00228	CcSEcCtD
Nitrofurantoin—Myalgia—Carmustine—lymphatic system cancer	0.000546	0.00228	CcSEcCtD
Nitrofurantoin—Paraesthesia—Bleomycin—lymphatic system cancer	0.000539	0.00224	CcSEcCtD
Nitrofurantoin—Malaise—Mitoxantrone—lymphatic system cancer	0.000538	0.00224	CcSEcCtD
Nitrofurantoin—Dyspnoea—Bleomycin—lymphatic system cancer	0.000535	0.00223	CcSEcCtD
Nitrofurantoin—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000534	0.00222	CcSEcCtD
Nitrofurantoin—Confusional state—Carmustine—lymphatic system cancer	0.000528	0.0022	CcSEcCtD
Nitrofurantoin—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000523	0.00218	CcSEcCtD
Nitrofurantoin—Decreased appetite—Bleomycin—lymphatic system cancer	0.000521	0.00217	CcSEcCtD
Nitrofurantoin—Myalgia—Vincristine—lymphatic system cancer	0.000521	0.00217	CcSEcCtD
Nitrofurantoin—Cough—Mitoxantrone—lymphatic system cancer	0.00052	0.00217	CcSEcCtD
Nitrofurantoin—Vomiting—Fludarabine—lymphatic system cancer	0.00052	0.00217	CcSEcCtD
Nitrofurantoin—Rash—Fludarabine—lymphatic system cancer	0.000516	0.00215	CcSEcCtD
Nitrofurantoin—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000513	0.00214	CcSEcCtD
Nitrofurantoin—Headache—Fludarabine—lymphatic system cancer	0.000512	0.00214	CcSEcCtD
Nitrofurantoin—Myalgia—Mitoxantrone—lymphatic system cancer	0.000508	0.00212	CcSEcCtD
Nitrofurantoin—Chest pain—Mitoxantrone—lymphatic system cancer	0.000508	0.00212	CcSEcCtD
Nitrofurantoin—Discomfort—Mitoxantrone—lymphatic system cancer	0.000502	0.00209	CcSEcCtD
Nitrofurantoin—Anaphylactic shock—Vincristine—lymphatic system cancer	0.0005	0.00208	CcSEcCtD
Nitrofurantoin—Anorexia—Carmustine—lymphatic system cancer	0.000499	0.00208	CcSEcCtD
Nitrofurantoin—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000494	0.00206	CcSEcCtD
Nitrofurantoin—Confusional state—Mitoxantrone—lymphatic system cancer	0.000491	0.00204	CcSEcCtD
Nitrofurantoin—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000489	0.00204	CcSEcCtD
Nitrofurantoin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000487	0.00203	CcSEcCtD
Nitrofurantoin—Nausea—Fludarabine—lymphatic system cancer	0.000486	0.00202	CcSEcCtD
Nitrofurantoin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000477	0.00199	CcSEcCtD
Nitrofurantoin—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000477	0.00199	CcSEcCtD
Nitrofurantoin—Anorexia—Vincristine—lymphatic system cancer	0.000476	0.00198	CcSEcCtD
Nitrofurantoin—Body temperature increased—Bleomycin—lymphatic system cancer	0.000474	0.00198	CcSEcCtD
Nitrofurantoin—Paraesthesia—Carmustine—lymphatic system cancer	0.00047	0.00196	CcSEcCtD
Nitrofurantoin—Dyspnoea—Carmustine—lymphatic system cancer	0.000467	0.00194	CcSEcCtD
Nitrofurantoin—Somnolence—Carmustine—lymphatic system cancer	0.000465	0.00194	CcSEcCtD
Nitrofurantoin—Anorexia—Mitoxantrone—lymphatic system cancer	0.000464	0.00193	CcSEcCtD
Nitrofurantoin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000455	0.0019	CcSEcCtD
Nitrofurantoin—Decreased appetite—Carmustine—lymphatic system cancer	0.000455	0.0019	CcSEcCtD
Nitrofurantoin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000452	0.00188	CcSEcCtD
Nitrofurantoin—Paraesthesia—Vincristine—lymphatic system cancer	0.000449	0.00187	CcSEcCtD
Nitrofurantoin—Constipation—Carmustine—lymphatic system cancer	0.000448	0.00187	CcSEcCtD
Nitrofurantoin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000443	0.00185	CcSEcCtD
Nitrofurantoin—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000442	0.00184	CcSEcCtD
Nitrofurantoin—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000437	0.00182	CcSEcCtD
Nitrofurantoin—Decreased appetite—Vincristine—lymphatic system cancer	0.000434	0.00181	CcSEcCtD
Nitrofurantoin—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000434	0.00181	CcSEcCtD
Nitrofurantoin—Somnolence—Mitoxantrone—lymphatic system cancer	0.000433	0.0018	CcSEcCtD
Nitrofurantoin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000431	0.0018	CcSEcCtD
Nitrofurantoin—Feeling abnormal—Carmustine—lymphatic system cancer	0.000431	0.0018	CcSEcCtD
Nitrofurantoin—Asthenia—Bleomycin—lymphatic system cancer	0.00043	0.00179	CcSEcCtD
Nitrofurantoin—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000428	0.00178	CcSEcCtD
Nitrofurantoin—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000428	0.00178	CcSEcCtD
Nitrofurantoin—Constipation—Vincristine—lymphatic system cancer	0.000427	0.00178	CcSEcCtD
Nitrofurantoin—Asthma—Methotrexate—lymphatic system cancer	0.000426	0.00178	CcSEcCtD
Nitrofurantoin—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000423	0.00176	CcSEcCtD
Nitrofurantoin—Eosinophilia—Methotrexate—lymphatic system cancer	0.000422	0.00176	CcSEcCtD
Nitrofurantoin—Constipation—Mitoxantrone—lymphatic system cancer	0.000416	0.00173	CcSEcCtD
Nitrofurantoin—Abdominal pain—Carmustine—lymphatic system cancer	0.000414	0.00172	CcSEcCtD
Nitrofurantoin—Body temperature increased—Carmustine—lymphatic system cancer	0.000414	0.00172	CcSEcCtD
Nitrofurantoin—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000409	0.0017	CcSEcCtD
Nitrofurantoin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000401	0.00167	CcSEcCtD
Nitrofurantoin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000398	0.00166	CcSEcCtD
Nitrofurantoin—Abdominal pain—Vincristine—lymphatic system cancer	0.000395	0.00165	CcSEcCtD
Nitrofurantoin—Body temperature increased—Vincristine—lymphatic system cancer	0.000395	0.00165	CcSEcCtD
Nitrofurantoin—Hypersensitivity—Carmustine—lymphatic system cancer	0.000386	0.00161	CcSEcCtD
Nitrofurantoin—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000385	0.0016	CcSEcCtD
Nitrofurantoin—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000385	0.0016	CcSEcCtD
Nitrofurantoin—Vomiting—Bleomycin—lymphatic system cancer	0.000381	0.00159	CcSEcCtD
Nitrofurantoin—Drowsiness—Methotrexate—lymphatic system cancer	0.00038	0.00158	CcSEcCtD
Nitrofurantoin—Rash—Bleomycin—lymphatic system cancer	0.000378	0.00158	CcSEcCtD
Nitrofurantoin—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000377	0.00157	CcSEcCtD
Nitrofurantoin—Asthenia—Carmustine—lymphatic system cancer	0.000376	0.00156	CcSEcCtD
Nitrofurantoin—Renal failure—Methotrexate—lymphatic system cancer	0.000374	0.00156	CcSEcCtD
Nitrofurantoin—Hypersensitivity—Vincristine—lymphatic system cancer	0.000368	0.00153	CcSEcCtD
Nitrofurantoin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000359	0.00149	CcSEcCtD
Nitrofurantoin—Asthenia—Vincristine—lymphatic system cancer	0.000359	0.00149	CcSEcCtD
Nitrofurantoin—Diarrhoea—Carmustine—lymphatic system cancer	0.000358	0.00149	CcSEcCtD
Nitrofurantoin—Nausea—Bleomycin—lymphatic system cancer	0.000356	0.00148	CcSEcCtD
Nitrofurantoin—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000355	0.00148	CcSEcCtD
Nitrofurantoin—Asthenia—Mitoxantrone—lymphatic system cancer	0.000349	0.00145	CcSEcCtD
Nitrofurantoin—Dizziness—Carmustine—lymphatic system cancer	0.000346	0.00144	CcSEcCtD
Nitrofurantoin—Diarrhoea—Vincristine—lymphatic system cancer	0.000342	0.00142	CcSEcCtD
Nitrofurantoin—Hepatitis—Methotrexate—lymphatic system cancer	0.000341	0.00142	CcSEcCtD
Nitrofurantoin—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000333	0.00139	CcSEcCtD
Nitrofurantoin—Vomiting—Carmustine—lymphatic system cancer	0.000333	0.00139	CcSEcCtD
Nitrofurantoin—Dizziness—Vincristine—lymphatic system cancer	0.00033	0.00138	CcSEcCtD
Nitrofurantoin—Rash—Carmustine—lymphatic system cancer	0.00033	0.00138	CcSEcCtD
Nitrofurantoin—Headache—Carmustine—lymphatic system cancer	0.000328	0.00137	CcSEcCtD
Nitrofurantoin—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000323	0.00134	CcSEcCtD
Nitrofurantoin—Vomiting—Vincristine—lymphatic system cancer	0.000318	0.00132	CcSEcCtD
Nitrofurantoin—Rash—Vincristine—lymphatic system cancer	0.000315	0.00131	CcSEcCtD
Nitrofurantoin—Headache—Vincristine—lymphatic system cancer	0.000313	0.0013	CcSEcCtD
Nitrofurantoin—Nausea—Carmustine—lymphatic system cancer	0.000311	0.0013	CcSEcCtD
Nitrofurantoin—Vomiting—Mitoxantrone—lymphatic system cancer	0.000309	0.00129	CcSEcCtD
Nitrofurantoin—Rash—Mitoxantrone—lymphatic system cancer	0.000307	0.00128	CcSEcCtD
Nitrofurantoin—Chills—Methotrexate—lymphatic system cancer	0.000306	0.00128	CcSEcCtD
Nitrofurantoin—Headache—Mitoxantrone—lymphatic system cancer	0.000305	0.00127	CcSEcCtD
Nitrofurantoin—Alopecia—Methotrexate—lymphatic system cancer	0.000302	0.00126	CcSEcCtD
Nitrofurantoin—Nausea—Vincristine—lymphatic system cancer	0.000297	0.00124	CcSEcCtD
Nitrofurantoin—Nausea—Mitoxantrone—lymphatic system cancer	0.000289	0.0012	CcSEcCtD
Nitrofurantoin—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000276	0.00115	CcSEcCtD
Nitrofurantoin—Anaemia—Methotrexate—lymphatic system cancer	0.000275	0.00114	CcSEcCtD
Nitrofurantoin—Malaise—Methotrexate—lymphatic system cancer	0.000268	0.00112	CcSEcCtD
Nitrofurantoin—Vertigo—Methotrexate—lymphatic system cancer	0.000267	0.00111	CcSEcCtD
Nitrofurantoin—Leukopenia—Methotrexate—lymphatic system cancer	0.000266	0.00111	CcSEcCtD
Nitrofurantoin—Cough—Methotrexate—lymphatic system cancer	0.000259	0.00108	CcSEcCtD
Nitrofurantoin—Chest pain—Methotrexate—lymphatic system cancer	0.000253	0.00105	CcSEcCtD
Nitrofurantoin—Myalgia—Methotrexate—lymphatic system cancer	0.000253	0.00105	CcSEcCtD
Nitrofurantoin—Discomfort—Methotrexate—lymphatic system cancer	0.00025	0.00104	CcSEcCtD
Nitrofurantoin—Confusional state—Methotrexate—lymphatic system cancer	0.000244	0.00102	CcSEcCtD
Nitrofurantoin—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000242	0.00101	CcSEcCtD
Nitrofurantoin—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000237	0.000989	CcSEcCtD
Nitrofurantoin—Anorexia—Methotrexate—lymphatic system cancer	0.000231	0.000963	CcSEcCtD
Nitrofurantoin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000221	0.00092	CcSEcCtD
Nitrofurantoin—Paraesthesia—Methotrexate—lymphatic system cancer	0.000218	0.000907	CcSEcCtD
Nitrofurantoin—Dyspnoea—Methotrexate—lymphatic system cancer	0.000216	0.000901	CcSEcCtD
Nitrofurantoin—Somnolence—Methotrexate—lymphatic system cancer	0.000216	0.000898	CcSEcCtD
Nitrofurantoin—Dyspepsia—Methotrexate—lymphatic system cancer	0.000213	0.000889	CcSEcCtD
Nitrofurantoin—Decreased appetite—Methotrexate—lymphatic system cancer	0.000211	0.000878	CcSEcCtD
Nitrofurantoin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000209	0.000872	CcSEcCtD
Nitrofurantoin—Feeling abnormal—Methotrexate—lymphatic system cancer	0.0002	0.000833	CcSEcCtD
Nitrofurantoin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000198	0.000826	CcSEcCtD
Nitrofurantoin—Abdominal pain—Methotrexate—lymphatic system cancer	0.000192	0.000799	CcSEcCtD
Nitrofurantoin—Body temperature increased—Methotrexate—lymphatic system cancer	0.000192	0.000799	CcSEcCtD
Nitrofurantoin—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000179	0.000744	CcSEcCtD
Nitrofurantoin—Asthenia—Methotrexate—lymphatic system cancer	0.000174	0.000725	CcSEcCtD
Nitrofurantoin—Diarrhoea—Methotrexate—lymphatic system cancer	0.000166	0.000691	CcSEcCtD
Nitrofurantoin—Dizziness—Methotrexate—lymphatic system cancer	0.00016	0.000668	CcSEcCtD
Nitrofurantoin—Vomiting—Methotrexate—lymphatic system cancer	0.000154	0.000642	CcSEcCtD
Nitrofurantoin—Rash—Methotrexate—lymphatic system cancer	0.000153	0.000637	CcSEcCtD
Nitrofurantoin—Headache—Methotrexate—lymphatic system cancer	0.000152	0.000633	CcSEcCtD
Nitrofurantoin—Nausea—Methotrexate—lymphatic system cancer	0.000144	0.0006	CcSEcCtD
